View NRG-HN002 PowerPoint Presentation
Principal Investigator/Radiation Oncology
Sue S. Yom, MD, PhD
To select the arm(s) achieving a 2-year progression-free survival rate of ≥ 85% without unacceptable swallowing toxicity at 1 year
Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls); patients must have positive immunohistochemical staining for p16, as confirmed by the NRG Oncology Biospecimen Bank, prior to randomization.
Activated October 27, 2014
CTSU - Available via the National Cancer Institute Cancer Trials Support Unit (CTSU) website.